



Docket No.54

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bowdish et al.
Application No: 10/006,593
Filing Date: December 5, 2001 Group Art: 1642
For: Rationally Designed Antibodies

1642
P#13
RECEIVED
AUG 21 2003
TECH CENTER 1600/2900


CERTIFICATE OF MAILING

Date of Deposit: August 15, 2003

I hereby certify that the following:

- ☒ This Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement
- ☒ PTO Form 1449 and Cited References
- ☒ Return Postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Lori Rooney

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410



Docket: 54 US

TECH CENTER 1600/2900

AUG 20 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bowdish et al.

Serial No: 10/006,593

Examiner: Larry R. Helms

Filed: December 5, 2001

Group Art Unit: 1642

For: Rationally Designed Antibodies

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56, Applicants submit the enclosed reference for the Examiner's consideration.

It is respectfully requested that the reference(s) submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the reference(s) is/are enclosed. This submission is believed to be in compliance with 37 C.F.R. §1.97 and 37 C.F.R. §1.98.

The citation of the listed item(s) is not a representation that it constitutes a complete or exhaustive listing of prior art or that it constitutes prior art. The item(s) listed is/are submitted in good faith, but is/are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner, it will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

() This information disclosure statement is being filed within three (3) months of the filing date of this application.

() This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application.

() To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action in connection with this case.

() Enclosed is a certificate under 37 C.F.R. §1.97 (e)(i).

() Enclosed is a petition under 37 C.F.R. §1.97 (d)

() Please charge the petition fee of \$130.00 required under 37 C.F.R. §1.17 (i)(1) to Deposit Account No. 01-0483.

(x) This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection of Notice of Allowance

(x) Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97 (e) (1); and no fee is required under 37 C.F.R. §1.17 (p).

() As set forth in 37 C.F.R. §1.97 (c), to the best of Applicant(s) knowledge, this information disclosure statement is being filed before either the mailing of a final action under 37 C.F.R. §1.113 or the mailing of a notice of allowance under 37 C.F.R. §1.113, and is accompanied by the \$220.00 fee as provided for in 37 C.F.R. §1.17(p).

() Please charge the \$240.00 fee required by 37 C.F.R. §1.17(p) to Deposit Account No. 01-0483.

(x) Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or 37 C.F.R. §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 01-0483. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend time as required and charge Deposit Account No. 01-0483 therefor. **TWO COPIES OF THIS SHEET ARE ENCLOSED.**

Early and favorable consideration of the case is respectfully requested.

Dated: August 11, 2003



Mark Farber
Registration No. 34,159
Attorney for Applicants

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
(203) 271-8319

Form PTO-1449 U.S. DEPARTMENT OF
COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

54 US

10/006, 193

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Bowdish et al.

FILING DATE

December 5, 2001

GROUP AND Unit:

1642

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 7 7 3 5 6 9	06/30/1998	Wrighton et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 0 2 4 7 8 2	05/04/2000	WO				
	0 0 6 1 6 3 7	10/19/2000	WO				
	9 9 1 0 4 9 4	03/04/1999	WO				
	9 9 2 5 3 7 8	05/27/1999	WO				
	9 6 4 0 1 8 9	12/19/1996	WO				
	9 5 1 1 3 1 7	04/27/1995	WO				
	9 5 2 9 6 9 0	11/09/1995	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	PCT Search Report
	Alexandre Jagerschmidt, Human Trombopietin Structure-Function Relationships: Identification Of Functionally Important Residues, Biochem.J. (1998) 333, 729-734
	Takumi Kamura, Characterization of Human Thrombopoietin Gene Promoter, The Journal Of Biological Chemistry, 1997 by The American Society for Biochemistry and Molecular Biology, Inc., Vol. 272, No. 17, Issue of April 25, pp. 11361-11368, 1997.
	Jeremy Cook, Recombinant Antibodies Containing an Engineered B-Cell Epitope Capable Of Eliciting Conformation-Specific Antibody Responses, Butterworth Heinemann, Vaccine, Vol. 13, No. 18, pp. 1770-1778, 1995, Elsevier Science Ltd.
	Hayden M S ET AL, Antibody Engineering, current Opinion in Immunology, Current Biology Ltd, XX, Vol. 9, No. 2, April 1997, pp. 201-212.
	Parhami-Seren B. ET AL, Selection of High Affinity P-Azophenyarsonate Fabs From Heavy-Chain CDR2 Insertaion Libraries, Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL, Vol. 259, No. 1-2, January 1, 2002

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449 [6-4])

TECH CENTER 1600/2000

AUG 20 2003

RECEIVED

Form PTO-1449 U.S. DEPARTMENT OF
COMMERCE PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

54 US

SERIAL NO.

10/006, 8

APPLICANT


Bowdish et al.

FILING DATE

December 5, 2001

GROUP A Unit:

1642



U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Chaiken I M et al., Identifying Structure-Function Relationships in Four-Helix Bundle Cytokines: Towards De Nova Mimetics Design, Trends in Biotechnology, Elsevier Publications, Cambridge, GB, Vol. 14, No. 10, October 1, 1996, pp 369-375.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.